BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:Simmons Comprehensive Cancer Center Distinguished Lecture Seri
 es
X-WR-TIMEZONE:Central Time (US & Canada)
BEGIN:VEVENT
DTSTAMP:20261016T144001Z
UID:tag:localist.com\,2008:EventInstance_51561446512898
DTSTART:20260121T180000Z
DTEND:20260121T190000Z
DESCRIPTION:Simmons Comprehensive Cancer Center Distinguished Lecture Serie
 s\n\n \n\n"Malignant Transformation and Precision Immunotherapy for B-Cell
  Lymphoma"\n\n \n\nGuest Speaker:\n\nAri Melnick\, M.D. FAACR\n\nDirector\
 n\nJosep Carreras Leukaemia Research Institute\n\n \n\nWednesday\, January
  21st | 12pm\n\nVirtual Zoom\n\n \n\nAbout Dr Ari Melnick\, M.D. FAACR\n\n
 Dr. Melnick is a recognized leader in the fields of hematologic malignanci
 es and cancer epigenetics. Among his major contributions are the first lar
 ge-scale epigenomic studies in humans\, which demonstrated that aberrant e
 pigenetic programming is a hallmark of cancer and that epigenetic diversit
 y is a key determinant of tumor fitness and poor clinical outcomes. These 
 findings led to important mechanistic insights — for example\, how mutat
 ions in IDH1 and IDH2 disrupt the epigenome through the production of an a
 berrant oncometabolite\, and how mutations in TET2\, WT1\, IDH1/2\, and FL
 T3 promote leukemogenesis through cooperative epigenetic reprogramming. Th
 is was the basis for him receiving the ASH Beutler Award for Outstanding T
 ranslational Research in 2020. Dr. Melnick has played a foundational role 
 in establishing the importance of epigenetic dysfunction in lymphomagenesi
 s\, elucidating the mechanistic roles of chromatin modifiers such as EZH2\
 , CREBBP\, EP300\, KDM1A\, KMT2D\, HIST1H1\, BTG1\, ARID1A\, TBL1XR1\, and
  TET2. He has also pioneered studies on nuclear topology and its role in r
 egulating the humoral immune response and the malignant transformation of 
 B cells. In the therapeutic arena\, Dr. Melnick has developed novel target
 ed therapies against key lymphoma oncoproteins such as BCL6\, SIRT3\, and 
 MALT1\, and has helped define the rationale for additional targets\, inclu
 ding EZH2. Several of these therapeutic approaches have received FDA appro
 val or progressed to phase III clinical trials. He has authored more than 
 350 scientific publications\, held numerous national leadership roles\, or
 ganized prominent scientific conferences\, and devoted extensive effort to
  mentoring trainees and junior faculty\, many of whom now lead distinguish
 ed careers in basic and translational research. Dr. Melnick serves on the 
 Board of Directors of both the Leukemia & Lymphoma Society and the Lymphom
 a Research Foundation. He also has extensive experience initiating and lea
 ding multi-center and international research consortia\, and is currently 
 the Principal Investigator of several program grants\, including two activ
 e LLS SCOR and RAFL programmatic grants. He recently took on the position 
 of the Josep Carreras Institute in Barcelona\, one of the only free-standi
 ng bench to bedside Blood Cancer Research center in the World
LOCATION:
SUMMARY:Simmons Comprehensive Cancer Center Distinguished Lecture Series
URL;VALUE=URI:https://events.utsouthwestern.edu/event/simmons-comprehensive
 -cancer-center-distinguished-lecture-series-6064
CATEGORIES:Academics & Co-Curricular
CATEGORIES:Research
CATEGORIES:Faculty
CATEGORIES:Lecture
CATEGORIES:Science & Technology
END:VEVENT
END:VCALENDAR